March 31, 2010 — A blood test may soon be able to identify which patients with multiple sclerosis will and will not respond to beta interferon. Only a reported two-thirds of patients with ...

NEW YORK (Reuters Health) - Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared data from those treated in the phase 3 EVOLVE-MS-1 and DECIDE studies. Treatment with ...

Disease activity despite interferon predicts poor MS outcomes In relapsing-remitting MS, disease activity after treatment with interferon (IFN)β-1a linked to poor long-term outcomes. HealthDay News — ...

LAS VEGAS, Sept. 26, 2023 /PRNewswire/ -- Heligenics, Inc., a pioneering biotechnology company applying functional genomics to drug discovery, announced today that it has reshaped the landscape of ...

Consuming large amounts of ultra-processed foods is associated with increased disease activity in people with early MS, a study has found.

Multiple sclerosis (MS) patients treated with ocrelizumab (Ocrevus) had a higher risk of infections over time than other MS patients, a real-world cohort study showed.

How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...

Multiple sclerosis (MS) could be "on the brink of a new class of treatment" after early trial results suggest two drugs may ...